Table 2.
Somatic mutations and their prognostic value in biliary tract cancers.
| Tumor group | Worse | Better | No effect |
|---|---|---|---|
| Biliary tract cancers |
ARID1A
KRAS a Del at 7q22.1 High TMB |
FGFR2
PRB1A |
CDKN2A, CDKN2B, IDH, PIK3CA, MYC alteration |
| Intrahepatic cholangiocarcinoma |
TP53
KRAS CDK2NA/B EGFR BAP1 a ARID1A a PBRM1 BRCA1/2 |
FGFR
(point mutations and translocations) IDH1 b |
CDK2NA
BRAF PTEN HER2 |
| Extrahepatic cholangiocarcinoma |
PBRM1
BAP1 c |
PIK3CA |
TP53
KRAS CDK2NB A1RD1 PBRM1 SMAD4 |
| Gallbladder cancers | None identified | None identified |
TP53
KRAS CDK2NA/B ARID1A IDH1 PIK3CA SMAD4 MYC |
TMB, tumor mutational burden.
a
No effect in one study and bad prognosis in others.
b
No effect in some studies and good prognosis in others.
c
PFS is different but not OS.